Immuron Receives FDA Feedback On Pre-IND Package For IMM-529 To Prevent Or Treat Clostridioides Difficile Infection (CDI); Plans To File IND Application In 1H 2025, Followed By Phase 2 Trial
Portfolio Pulse from Benzinga Newsdesk
Immuron has received feedback from the FDA on its pre-IND package for IMM-529, a treatment for Clostridioides difficile infection. The company plans to file an IND application in the first half of 2025, followed by a Phase 2 trial.
September 05, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuron has received FDA feedback on its pre-IND package for IMM-529, aimed at treating Clostridioides difficile infection. The company plans to file an IND application in the first half of 2025, followed by a Phase 2 trial.
The FDA feedback is a positive step for Immuron's IMM-529, indicating progress in its development pipeline. The planned IND filing and subsequent Phase 2 trial suggest potential future growth and investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100